| Patent application number | Description | Published |
|---|
| 20090047340 | LIPOSOMAL REDUCED GLUTATHIONE AND 1-ARGININE, INCLUDING WITH OTHER INGREDIENT(S), CAPABLE OF MULTIPATH ADMINISTRATION FOR REVERSAL AND PREVENTION OF OBESITY AND FOR MITOCHONDRIAL BIOGENESIS - The invention enables management of mammalian disease related to decreased energy production in the mitochondria, the powerhouse of the cell. The invention uses the combination of liposomal reduced glutathione and l-arginine to increase the ability weight loss in individuals with excess weight. The mechanism of weight loss appears to be related to improving the inefficient production of energy by the respiratory transport chain of mitochondria, the function of which are influenced positively by the availability of antioxidant nitric oxide in a non-oxidized environment. This invention enables weight loss in individuals who's inability to lose weight is related to inefficiency of the biochemical pathways facilitating mitochondrial function and energy production. The pathways related to inability to lose weight are also related to the phenomenon of the inability to metabolize fats, which results in insulin resistance and diabetes. The invention is useful for the management of the metabolic syndrome. The metabolic syndrome is actually a group of metabolic factors associated with an increased risk of vascular disease problems. The invention is also useful for the resolution of fatigue that accompanies both weight gain and illnesses. The ability of the invention to increase the production of the biochemical agmatine in the central nervous system as well generally in the body is part of the benefit of the combination of liposomal reduced glutathione and l-arginine. In addition, the biochemical pathways stimulated by this invention can have a beneficial effect in individuals suffering from a variety of infectious diseases. | 02-19-2009 |
| 20090068253 | METHOD FOR THE TREATMENT OF INFECTION WITH HHV-6 VIRUS AND THE AMELIORATION OF SYMPTOMS RELATED TO VIRUS USING LIPOSOMAL ENCAPSULATION FOR DELIVERY OF REDUCED GLUTATHIONE - The invention is the use of a therapeutically effective amount of glutathione (reduced) in a liposome encapsulation for oral administration to improve symptoms of illnesses that are related to viruses and for the treatment and prevention of virus, particularly HHV-6 and EBV, which liposomal encapsulation of glutathione (reduced) is referred to as liposomal glutathione. The application references specifically reduced glutathione and its importance, and how to stabilize it effectively so it can be taken orally, and need not be refrigerated. New uses for tuberculosis, and asthma are discussed. The combination is proposed of reduced glutathione and Highly Active Anti-Retroviral Therapy having at least one pharmaceutical composition selected from the group of Nucleoside/tide Reverse Transcriptase Inhibitors (NRTIs), Protease Inhibitors (PIs), and Non-nucleoside Reverse Transcriptase Inhibitors (NnRTIs). | 03-12-2009 |
| 20100166846 | MANAGEMENT OF MYOCLONUS WITH ORAL LIPOSOMAL REDUCED GLUTATHIONE - The invention relates to a composition and method for the management of myoclonus and myoclonus and other illnesses related to mold toxin exposure. | 07-01-2010 |
| 20100233193 | SYSTEMIC ADMINISTRATION OF NAC FOR VACCINATION PROPHYLAXIS - The invention is for the combination and related methods of N-acetyl-cysteine oral, inhaled, or intravenous, or glutathione inhaled or intravenous, generally in combination with antibiotic and /or antiviral therapy to ameliorate the toxic effects of infection with materials used in Bioterror incidents such as | 09-16-2010 |
| 20100233297 | SYSTEMIC ADMINISTRATION OF NAC AS AN ADJUNCT IN THE TREATMENT OF TERRORISM EXPOSURES SUCH AS RADIATION AND FOR PROPHYLAXIS - The invention is for the combination and related methods of N-acetyl-cysteine oral, inhaled, or intravenous, or glutathione inhaled or intravenous, generally in combination with antibiotic and/or antiviral therapy to ameliorate the toxic effects of infection with materials used in Bioterror incidents such as | 09-16-2010 |
| 20100291196 | METHOD OF TREATMENT OF AUTISM SPECTRUM DISORDER WITH LIPOSOMAL REDUCED GLUTATHIONE - The invention proposes the use of reduced glutathione encapsulated in a liposome (liposomal reduced glutathione) for the oral administration of a therapeutically effective amount to improve symptoms in disease states related to diminished function of the methylation pathway such as autism, other neurodegenerative diseases and abnormalities of neurotransmitter levels in urine or blood. The invention also proposes combining liposomal encapsulated methylcobalamin, and/or liposomal encapsulated Insulin Growth Factor 1 (IGF-1) with liposomal reduced glutathione to accomplish such improvement. | 11-18-2010 |
| 20100316700 | SYSTEMIC ADMINISTRATION OF LIPOSOMAL REDUCED GLUTATHIONE FOR THE DECORPORATION OF RADIOACTIVE MATERIALS AND NON-RADIOACTIVE MERCURY - The invention is for the combination and related methods of liposomal reduced glutathione in oral, inhaled, or intravenous, or glutathione inhaled or intravenous, to ameliorate the effects of exposure to or ingestion of radiation or radioactive materials, as treatment to ameliorate the toxic effects of radiation exposure or ingestion and to facilitate the decorporation of radioactive materials such as Co-60. The invention may also be used in conjunction with a decorporation agent such as DTPA, EDTA, DMPS or penicillamine to ameliorate the toxic effects of exposure or ingestion of radioactive agents or other toxic metals. | 12-16-2010 |
| 20110020436 | TOPICAL APPLICATION OF MELATONIN DIRECTLY OR IN LIPOSOMES FOR THE AMELIORATION OF ITCHING AND HISTAMINE AND NON-HISTAMINE RELATED INFLAMMATORY SKIN CHANGES - The invention is a topical therapeutically effective amount of melatonin encapsulated in a liposome applied topically to an area of skin affected by immunologic response, radiation treatment induced dermatitis, acne, insect bite or other irritant stimulus such as sunburn in order to reduce itching. The invention also proposes a topical therapeutically effective amount of melatonin and reduced glutathione encapsulated in a liposome applied topically to an area of skin for relief of those afflictions. | 01-27-2011 |
| 20110129523 | Liposomally Encapsulated Reduced Glutathione, including with Other Pharmacologic Preparation, Capable of Administration as an Oral, Topical, Intraoral or Transmucosal, Prepartion, for Reversal and Prevention of Oxidation of Cholesterol and of Low Density Lipoprotein - The invention proposes the sure of reduced glutathione in a liposome (liposomal reduced glutathione) for the oral administration of a therapeutically effective amount to ameliorate the progression of vascular disease, including atherosclerosis, diabetes, hypertension, narrowing of arteries leading to decreased blood flow, ischemic events, and the formation of blood clots, abnormal platelet aggregation, and thrombotic events, by reducing the amount and effect of oxidized cholesterol, oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with statin drugs to improve the effect of lowering not only cholesterol but also the oxidized cholesterol as well as oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with CoQ10 as a therapy for vascular disease and management of side effects of statin therapy. | 06-02-2011 |
